Jardiance Medicare Advantage Coverage: How to Get Empagliflozin for Less in 2026

What Medicare Advantage Plans Typically Cover for Jardiance

The majority of Medicare Advantage Prescription Drug (MAPD) plans include empagliflozin on their formularies, though placement varies by insurer and region. Jardiance most often appears on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), which means monthly copays generally fall between $35 and $100 before any catastrophic coverage kicks in.

Medicare Advantage plans are offered by private insurers (UnitedHealthcare, Humana, Aetna, CVS/Caremark affiliates, and others) that contract with the Centers for Medicare & Medicaid Services (CMS). Each plan sets its own formulary, tier placement, and prior authorization rules. A 2023 CMS analysis found that SGLT2 inhibitors were included on over 95% of stand-alone Part D and MAPD formularies, reflecting the growing evidence base for this drug class. Still, tier placement and cost-sharing differ significantly between plans, so checking your specific plan's formulary is a necessary first step.

The EMPA-REG OUTCOME trial (N=7,020) demonstrated that empagliflozin reduced the risk of cardiovascular death by 38% in patients with type 2 diabetes and established cardiovascular disease over a median follow-up of 3.1 years 1. That trial reshaped prescribing and contributed to SGLT2 inhibitors earning a prominent position in the American Diabetes Association (ADA) Standards of Care, which recommend empagliflozin or another SGLT2 inhibitor for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease or are at high cardiovascular risk [2].

Because of this evidence, many Medicare Advantage plans classify Jardiance as a preferred brand, particularly for beneficiaries with documented heart failure or cardiovascular risk factors. Plans that restrict it to Tier 4 often allow a tier exception request supported by clinical documentation.

How the Inflation Reduction Act Changes Your Jardiance Costs

Starting January 2025, the Inflation Reduction Act (IRA) caps total out-of-pocket Part D spending at $2,000 per year for all Medicare beneficiaries. This single policy change is the most consequential cost reduction for Jardiance users on Medicare Advantage in recent years.

Before the IRA cap, a beneficiary on a non-preferred brand tier paying $95 per month for Jardiance would spend $1,140 annually on that drug alone, and total Part D out-of-pocket costs could climb much higher if other brand-name medications were involved. Under the new cap, once a beneficiary's cumulative out-of-pocket Part D spending hits $2 to 000 in a calendar year, they pay nothing for the remainder of the year. CMS also introduced a Medicare Prescription Payment Plan option that lets beneficiaries spread their out-of-pocket costs across monthly installments, eliminating large upfront pharmacy bills.

The Congressional Budget Office estimated that roughly 1.4 million Medicare Part D enrollees would benefit from the $2,000 cap in its first year. For patients taking Jardiance alongside other costly medications (statins, antihypertensives, insulin), the cap provides a hard ceiling on annual drug spending that did not exist before 2025.

One detail worth noting: the IRA also eliminated the 5% coinsurance that beneficiaries previously owed in the catastrophic coverage phase. That change means true $0 cost-sharing once the $2,000 threshold is reached 3.

Prior Authorization and Step Therapy Requirements

Many Medicare Advantage plans require prior authorization or step therapy before covering Jardiance. A typical step therapy protocol requires documented failure of or intolerance to metformin before approving an SGLT2 inhibitor.

According to a 2022 ADA position statement, SGLT2 inhibitors can be initiated as first-line therapy alongside metformin or even as monotherapy in patients with compelling cardiovascular or renal indications. If your Medicare Advantage plan requires step therapy, your prescribing clinician can submit a coverage determination request citing the ADA guidelines and the patient's specific cardiovascular or heart failure diagnosis.

The request process usually involves completing the plan's prior authorization form and attaching relevant clinical notes. Response times vary, but CMS requires Medicare Advantage plans to issue standard coverage decisions within 72 hours for prescription drugs and 24 hours for expedited requests 4. If denied, beneficiaries have the right to appeal, and CMS data shows that roughly 40% of Part D appeals at the first level result in favorable outcomes for the beneficiary.

For patients with a heart failure diagnosis (HFrEF or HFpEF), the path to approval is often shorter. The EMPEROR-Reduced trial (N=3,730) showed empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure by 25% compared to placebo 5. The EMPEROR-Preserved trial (N=5,988) extended that benefit to patients with preserved ejection fraction, with a 21% reduction in the same composite endpoint 6. These trials led to FDA approval of Jardiance for heart failure regardless of ejection fraction, and many Medicare Advantage plans have updated their criteria accordingly.

Why the Manufacturer Copay Card Does Not Work with Medicare

Boehringer Ingelheim offers a savings card for Jardiance that can reduce copays to as little as $10 per month. This card is available to commercially insured patients only. It cannot be applied to prescriptions paid by Medicare, Medicaid, TRICARE, or other federal or state healthcare programs.

The reason is regulatory. The federal Anti-Kickback Statute prohibits pharmaceutical manufacturers from offering financial incentives that could influence prescribing decisions for government-funded healthcare beneficiaries 7. The Office of Inspector General (OIG) has consistently interpreted manufacturer copay assistance programs for Medicare patients as potential violations of this statute.

This means Medicare Advantage beneficiaries must rely on the plan's formulary pricing, the IRA's $2,000 out-of-pocket cap, and any applicable Low-Income Subsidy (LIS) or Extra Help programs rather than manufacturer coupons. We cover alternative cost-reduction strategies below.

Strategies to Lower Your Jardiance Cost on Medicare Advantage

Several concrete approaches can reduce what you pay for empagliflozin under Medicare Advantage. Not every strategy applies to every patient, but reviewing each one with your prescriber or pharmacist is worth the effort.

Apply for Medicare Extra Help (Low-Income Subsidy). Beneficiaries with limited income and resources may qualify for Extra Help, which can reduce Part D premiums, deductibles, and copays. In 2026, individuals with annual income below approximately $22,590 and resources below $17,220 may qualify. The Social Security Administration processes Extra Help applications. Approved applicants pay no more than $4.50 for generic drugs and $11.20 for brand-name drugs per prescription (2025 figures, adjusted annually).

Request a tier exception. If your plan places Jardiance on a non-preferred brand tier, your physician can submit a tier exception request to move it to the preferred tier, lowering your copay. The request must include clinical justification explaining why empagliflozin is medically necessary and why alternatives (such as dapagliflozin or canagliflozin) are inappropriate.

Compare plans during Open Enrollment. Medicare's Annual Enrollment Period (October 15 through December 7) allows beneficiaries to switch plans. Use the Medicare Plan Finder tool to compare Jardiance copays across available MAPD plans in your ZIP code. Tier placement and copay amounts for the same drug can vary by $40 or more per month between plans in the same county.

Ask about therapeutic alternatives. Dapagliflozin (Farxiga) is another SGLT2 inhibitor with a similar evidence base. Some Medicare Advantage plans place dapagliflozin on a lower tier than empagliflozin. The DAPA-HF trial (N=4,744) showed comparable heart failure outcomes. Your clinician can determine whether switching within the SGLT2 class is clinically appropriate.

Use the Medicare Prescription Payment Plan. Even if your annual Jardiance cost stays the same, spreading payments across 12 equal monthly installments (available since January 2025) prevents a large upfront hit at the pharmacy counter during the deductible phase.

Empagliflozin's Expanding Indications and Coverage Implications

Jardiance has accumulated FDA approvals beyond type 2 diabetes, and each new indication can affect how Medicare Advantage plans categorize the drug on their formularies.

The original 2014 FDA approval covered type 2 diabetes. In 2022, the FDA expanded the label to include heart failure with reduced ejection fraction, and in 2023, approved it for heart failure regardless of ejection fraction based on the EMPEROR-Preserved data 6. A supplemental approval for chronic kidney disease followed, supported by the EMPA-KIDNEY trial (N=6,609), which demonstrated a 28% reduction in the composite of kidney disease progression or cardiovascular death 8.

These expanded indications matter for Medicare coverage because they give clinicians additional diagnostic codes to cite on prior authorization requests. A patient prescribed Jardiance for heart failure (ICD-10 code I50.x) or chronic kidney disease (N18.x) may face a different coverage pathway than one prescribed it solely for type 2 diabetes (E11.x). Some plans have separate formulary criteria for cardiovascular and renal indications that bypass the step therapy requirement for diabetes.

The 2024 AHA/ACC/HFSA heart failure guideline update gives SGLT2 inhibitors a Class I recommendation (strongest level) for patients with heart failure, irrespective of ejection fraction or diabetes status [9]. This guideline strength provides strong support for coverage requests.

What to Do If Your Plan Denies Jardiance Coverage

A denial is not the end of the process. Medicare Advantage beneficiaries have a structured, multi-level appeals process guaranteed by federal regulation.

Level 1: Plan Reconsideration. Submit a written appeal to the plan within 60 days of the denial. Include your physician's letter of medical necessity, relevant clinical notes, lab values (HbA1c, eGFR, NT-proBNP as applicable), and citations to the ADA Standards of Care or ACC/AHA heart failure guidelines. The plan must respond within 7 days for a standard request or 72 hours for an expedited request.

Level 2: Independent Review Entity (IRE). If the plan upholds the denial, CMS assigns the case to an IRE for independent review. The IRE must issue a decision within 7 days. CMS reports that approximately 50% of Part D cases reviewed by the IRE are decided in favor of the beneficiary.

Level 3 and beyond. Subsequent appeal levels include an Administrative Law Judge hearing (for claims exceeding $190 in 2025), the Medicare Appeals Council, and federal district court. Most Jardiance coverage disputes are resolved at Level 1 or Level 2.

Throughout this process, your physician's documentation carries significant weight. A clear letter stating the clinical rationale, failed alternatives, and relevant trial data (EMPA-REG OUTCOME, EMPEROR-Reduced, EMPEROR-Preserved, EMPA-KIDNEY) substantially improves the likelihood of a favorable outcome.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the ADA, noted in a 2023 ADA media briefing: "Access barriers to SGLT2 inhibitors remain one of the most significant gaps between guideline recommendations and real-world care for people with diabetes and cardiovascular disease" 10. That gap underscores why persistent appeals are worth pursuing.

Checking Your Specific Plan's Formulary

Every Medicare Advantage plan publishes its formulary online. You can verify Jardiance coverage in three ways: visit your plan's website and search the drug formulary, call the plan's member services number on the back of your insurance card, or use the Medicare.gov Plan Finder tool.

When reviewing the formulary, note four things: the tier assignment, whether prior authorization is required, whether step therapy applies, and any quantity limits. Some plans limit Jardiance to 30 tablets per 30-day fill, which aligns with standard dosing (one 10 mg or 25 mg tablet daily). Others may impose a 90-day supply requirement for mail-order pharmacy, which can sometimes reduce per-unit cost.

The ADA recommends that clinicians and patients review Part D formulary placement annually because plans can change tier assignments each January 2. A drug that was Tier 3 in 2025 may shift to Tier 4 in 2026, or vice versa, making Annual Enrollment Period comparisons a yearly task.

Beneficiaries filling Jardiance at a plan-preferred pharmacy (often a specific retail chain or mail-order service) may pay lower copays than at non-preferred pharmacies. This difference can be $15 to $30 per fill, making pharmacy selection a practical cost lever.